NCT01830777View on ClinicalTrials.gov

Brentuximab Vedotin + Re-induction Chemotherapy for AML

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

May 31, 2019

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Brentuximab Vedotin

Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy

DRUG

Mitoxantrone

Intravenously on Days 3-7 of re-induction therapy.

DRUG

Etoposide

Intravenously on Days 3-7 of re-induction therapy.

DRUG

Cytarabine

Intravenously on Days 3-7 of re-induction therapy.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01830777 - Brentuximab Vedotin + Re-induction Chemotherapy for AML | Biotech Hunter | Biotech Hunter